shares hit ms drug suspension
shares elan biogen idec plunged monday firms suspended sales multiple sclerosis drug tysabri patient death
york stock exchange shares elan lost partner biogen idec firms action death central nervous system disease suspected condition cited involved tysabri avonex biogen idec existing multiple sclerosis drug companies reports rare condition progressive multifocal leukoencephalopathy pml patients tysabri avonex tysabri approved november tipped leading multiple sclerosis treatment
companies clinical investigators evaluate patients consult leading experts understand risk pml firms statement outcome evaluations determine dosing clinical trials future commercial availability
analysts believed product provide growth opportunity biogen idec faced increased competition rivals avonex elan biggest firm irish stock exchange expected receive boost product inquiry elan accounts brought close bankruptcy firm rebuilding share price increasing company tysabri ian hunter goodbody stockbrokers dublin question mark elan finished biogen fell
shares uk pharmaceutical firm phytopharm closed pence london stock exchange monday partner set pull deal experimental alzheimer disease treatment phytopharm japan yamanouchi pharmaceutical licensing agreement prompting analysts raise questions level future cash reserves
